Induction of Humoral and Cellular Immunity by Intradermal Delivery of SARS-CoV-2 Nucleocapsid Protein Using Dissolvable Microneedles

Chaiyaporn Kuwentrai,Jinming Yu,Bao-zhong Zhang,Ye-fan Hu,Ying Dou,Hua-rui Gong,Jian-Dong Huang,Chenjie Xu
DOI: https://doi.org/10.1155/2021/5531220
IF: 4.4929
2021-05-17
Journal of Immunology Research
Abstract:The nucleocapsid protein (NP) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contains immunogenic epitopes that can induce cytotoxic T lymphocyte (CTL) against viral infection. This makes the nucleocapsid protein a suitable candidate for developing a vaccine against SARS-CoV-2 infection. This article reports the intradermal delivery of NP antigen using dissolvable microneedle skin patches that could induce both significant B cell and T cell responses.
immunology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to develop a non - spike protein vaccine candidate for SARS - CoV - 2 infection. Specifically, the researchers explored the use of soluble microneedle skin patches for the intradermal delivery of the SARS - CoV - 2 nucleocapsid protein (NP) to induce significant B - cell and T - cell immune responses. This method aims to overcome the possible limitations of existing spike - protein - based vaccines, such as weakened protection against viral variants, and to provide more long - lasting or more comprehensive protective immune responses. ### Research Background and Objectives - **Background**: SARS - CoV - 2 has caused a global pandemic. Although multiple spike - protein - based vaccines are currently being tested, these vaccines have not yet achieved complete immune protection in the population. In addition, spike - protein - based vaccines have limited protection against emerging viral variants. Therefore, researchers began to explore non - spike - protein vaccine candidates in order to obtain more long - lasting or more comprehensive protective immunity. - **Objective**: This study aims to evaluate the effectiveness of delivering the SARS - CoV - 2 nucleocapsid protein (NP) through soluble microneedle skin patches, especially its potential in inducing humoral immunity and cellular immunity. ### Research Methods - **Material Preparation**: The researchers prepared soluble microneedle patches containing the SARS - CoV - 2 nucleocapsid protein (NP). The microneedles were composed of low - molecular - weight hyaluronic acid (HA) and aluminum hydroxide gel. - **Animal Experiments**: BALB/c mice were divided into three groups and received subcutaneous injection of NP, NP delivered by microneedles, and the control group (microneedles without NP), respectively. Immunizations were carried out on day 0, day 3, and day 7, and blood samples were collected on day 14, day 21, and day 28 for ELISA testing. - **Immune Response Evaluation**: - **B - cell Antibody Response**: The levels of NP - specific IgG antibodies in mouse sera were detected by ELISA. - **T - cell Response**: The secretion of IFN - γ in splenocytes was detected by ELISPOT. - **Immunohistochemical Staining of Lung Tissue**: CD4 and CD8 T - cell markers in mouse lung tissues were observed by fluorescence confocal microscopy. ### Main Results - **B - cell Antibody Response**: Both NP delivery by microneedles and subcutaneous injection of NP could significantly induce the production of NP - specific IgG antibodies, and there was no significant difference between them. The antibody titer began to increase on day 14, further increased on day 21, and reached the highest value on day 28. - **T - cell Response**: Both NP delivery by microneedles and subcutaneous injection of NP could significantly induce T - cells to secrete IFN - γ, indicating that both methods could effectively activate the cellular immune response. - **Immunohistochemistry of Lung Tissue**: After NP delivery by microneedles, the presence of CD4 and CD8 T - cells was detected in mouse lung tissues, which may contribute to the protection against SARS - CoV - 2. ### Discussion and Conclusions - **Conclusion**: The research results show that delivering the SARS - CoV - 2 nucleocapsid protein (NP) using soluble microneedle skin patches can effectively induce B - cell antibody responses and T - cell immune responses. This method has the advantages of being non - invasive, easy to use, and low - cost, and is expected to become an important direction for future vaccine development. - **Future Prospects**: The researchers plan to further optimize the microneedle vaccine technology, including ensuring the sterile production of the device, cost - effectiveness in large - scale manufacturing, and developing a consistent microneedle deployment device. In addition, they also plan to explore the possibility of combining NP vaccines with spike - protein - based vaccines to enhance the effectiveness of vaccines.